EMA CVMP Meeting Highlights — 10–12 February 2026

18th February 2026

Summary: At its 10–12 February 2026 session, the CVMP adopted positive opinions on veterinary medicines and variations including a marketing authorisation for Emepax (maropitant) for managing nausea and vomiting in dogs. The Committee also recommended variations to existing vaccines and therapies — for example Bluevac BTV (expanded serotypes), a needle-free delivery option for Suvaxyn PRRS MLV, and updated safety information for products such as Bravecto, Coxevac and Yurvac RHD based on recent signal management results. CVMP also adopted scientific advice reports for several products (biological/non-immunological and immunological) and granted a limited market classification for a salmon immunological product.

In the regulatory guidance area, the Committee issued a certificate for a vaccine platform technology master file (vPTMF), adopted revised Q&A and new guidelines on elemental impurities and quality expectations, and opened a draft guideline on mRNA vaccines for veterinary use for public consultation. A concept paper was also adopted to revise the veterinary pharmacovigilance guideline on signal management, and a revised international standard (VICH GL34 (R1)) on mycoplasma testing was endorsed.

Link: https://www.ema.europa.eu/en/news/meeting-highlights-committee-veterinary-medicinal-products-cvmp-10-12-february-2026

Back to Recent News